Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $431.12 million. The enterprise value is $213.07 million.
Important Dates
The next estimated earnings date is Saturday, November 16, 2024, before market open.
Earnings Date | Nov 16, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CTNM has 25.72 million shares outstanding. The number of shares has increased by 238.72% in one year.
Shares Outstanding | 25.72M |
Shares Change (YoY) | +238.72% |
Shares Change (QoQ) | +885.86% |
Owned by Insiders (%) | 1.54% |
Owned by Institutions (%) | 27.70% |
Float | 12.69M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.98 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 58.92, with a Debt / Equity ratio of 0.00.
Current Ratio | 58.92 |
Quick Ratio | 58.48 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$638,742 |
Employee Count | 31 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -279,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 17.80 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 45.18 |
Average Volume (20 Days) | 77,654 |
Short Selling Information
The latest short interest is 952,350, so 3.70% of the outstanding shares have been sold short.
Short Interest | 952,350 |
Short Previous Month | 926,720 |
Short % of Shares Out | 3.70% |
Short % of Float | 7.51% |
Short Ratio (days to cover) | 20.60 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -38.62M |
Pretax Income | n/a |
Net Income | -19.80M |
EBITDA | -38.42M |
EBIT | -38.62M |
Earnings Per Share (EPS) | -$2.61 |
Full Income Statement Balance Sheet
The company has $218.65 million in cash and $597,000 in debt, giving a net cash position of $218.06 million or $8.48 per share.
Cash & Cash Equivalents | 218.65M |
Total Debt | 597,000 |
Net Cash | 218.06M |
Net Cash Per Share | $8.48 |
Equity (Book Value) | 217.50M |
Book Value Per Share | 8.46 |
Working Capital | 216.58M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$32.56 million and capital expenditures -$597,000, giving a free cash flow of -$33.15 million.
Operating Cash Flow | -32.56M |
Capital Expenditures | -597,000 |
Free Cash Flow | -33.15M |
FCF Per Share | -$1.29 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -238.72% |
Shareholder Yield | -238.72% |
Earnings Yield | -4.59% |
FCF Yield | -7.69% |
Analyst Forecast
The average price target for CTNM is $29.50, which is 76.01% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $29.50 |
Price Target Difference | 76.01% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CTNM has an Altman Z-Score of 63.84 and a Piotroski F-Score of 1.
Altman Z-Score | 63.84 |
Piotroski F-Score | 1 |